Inscrição na biblioteca: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publicou 6 edições por ano

ISSN Imprimir: 1045-4403

ISSN On-line: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

The Development of Monoclonal Antibodies for the Therapy of Cancer

Volume 8, Edição 3-4, 1998, pp. 321-356
DOI: 10.1615/CritRevEukarGeneExpr.v8.i3-4.50
Get accessGet access

RESUMO

Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.

CITADO POR
  1. Davol Pamela A., Smith Janelle A., Kouttab Nicola, Elfenbein Gerald J., Lum Lawrence G., Anti-CD3 × Anti-HER2 Bispecific Antibody Effectively Redirects Armed T Cells to Inhibit Tumor Development and Growth in Hormone-Refractory Prostate Cancer–Bearing Severe Combined Immunodeficient Beige Mice, Clinical Prostate Cancer, 3, 2, 2004. Crossref

  2. Neyt Mattias, Cost Considerations for Monoclonal Antibody-Targeted Therapy in Cancer, American Journal of Cancer, 5, 1, 2006. Crossref

  3. Goldstein D., Lambert G., Puisieux Fr., Benita S., Les systèmes colloïdaux de délivrance de médicaments ont-ils aidé à répondre aux espérances thérapeutiques des découvertes de biotechnologie ?, Annales Pharmaceutiques Françaises, 63, 1, 2005. Crossref

  4. Quan Maureen, Carter Paul, The Rise of Antibodies as Therapeutics, in IgE and Anti-IgE Therapy in Asthma and Allergic Disease, 20023077, 2002. Crossref

  5. Oh Phil, Li Yan, Yu Jingyi, Durr Eberhard, Krasinska Karolina M., Carver Lucy A., Testa Jacqueline E., Schnitzer Jan E., Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy, Nature, 429, 6992, 2004. Crossref

  6. Qu C F, Li Y, Song Y J, Rizvi S M A, Raja C, Zhang D, Samra J, Smith R, Perkins A C, Apostolidis C, Allen B J, MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate, British Journal of Cancer, 91, 12, 2004. Crossref

  7. Sen Manjula, Wankowski Dawn M., Garlie Nina K., Siebenlist Ruth E., Van Epps Dennis, LeFever Ann V., Lum Lawrence G., Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+Tumors, Journal of Hematotherapy & Stem Cell Research, 10, 2, 2001. Crossref

  8. Khawli Leslie A., Biela Barbara H., Hu Peisheng, Epstein Alan L., Stable, Genetically Engineered F(ab′)2Fragments of Chimeric TNT-3 Expressed in Mammalian Cells, Hybridoma and Hybridomics, 21, 1, 2002. Crossref

  9. Newsome Barrett W., Ernstoff Marc S., The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?, British Journal of Clinical Pharmacology, 66, 1, 2008. Crossref

  10. DeNardo Sally J, Kroger Linda A, DeNardo Gerald L, A new era for radiolabeled antibodies in cancer?, Current Opinion in Immunology, 11, 5, 1999. Crossref

  11. Goldstein Danny, Nassar Taher, Lambert Gregory, Kadouche Jean, Benita Simon, The design and evaluation of a novel targeted drug delivery system using cationic emulsion–antibody conjugates, Journal of Controlled Release, 108, 2-3, 2005. Crossref

  12. Popkov M, Sidrac-Ghali S, Lusignan Y, Lemieux S, Mandeville R, Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9, European Journal of Cancer, 37, 18, 2001. Crossref

  13. Madhusudan Srinivasan, Ganesan Trivadi S., Tyrosine kinase inhibitors in cancer therapy, Clinical Biochemistry, 37, 7, 2004. Crossref

  14. Bézian Jean-Henri, Moynet Daniel, Comeau Sylvie, Chagnaud Jean-Luc, L'ingénierie des anticorps et ses applications, Revue Française des Laboratoires, 2000, 327, 2000. Crossref

  15. Borrebaeck Carl A.K, Antibodies in diagnostics – from immunoassays to protein chips, Immunology Today, 21, 8, 2000. Crossref

  16. Zwick Esther, Bange Johannes, Ullrich Axel, Receptor tyrosine kinases as targets for anticancer drugs, Trends in Molecular Medicine, 8, 1, 2002. Crossref

  17. Hudson Peter J, Kortt Alexander A, High avidity scFv multimers; diabodies and triabodies, Journal of Immunological Methods, 231, 1-2, 1999. Crossref

  18. Glennie Martin J, Johnson Peter W.M, Clinical trials of antibody therapy, Immunology Today, 21, 8, 2000. Crossref

  19. Mitra Siddhartha, Li Gordon, Harsh Griffith R., Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas, Neurosurgery Clinics of North America, 21, 1, 2010. Crossref

  20. Kleinschmidt Martin, Rudolph Rainer, Lilie Hauke, Design of a Modular Immunotoxin Connected by Polyionic Adapter Peptides, Journal of Molecular Biology, 327, 2, 2003. Crossref

  21. Tamilvanan Shunmugaperumal, Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body, International Journal of Pharmaceutics, 381, 1, 2009. Crossref

  22. Hudson Peter J, Recombinant antibody constructs in cancer therapy, Current Opinion in Immunology, 11, 5, 1999. Crossref

  23. Zola Heddy, Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies, Expert Opinion on Biological Therapy, 1, 3, 2001. Crossref

  24. Binyamin Liat, Borghaei Hossein, Weiner Louis M., Cancer therapy with engineered monoclonal antibodies, Update on Cancer Therapeutics, 1, 2, 2006. Crossref

  25. Buolamwini John K, Novel anticancer drug discovery, Current Opinion in Chemical Biology, 3, 4, 1999. Crossref

  26. Tamilvanan S., Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems, Progress in Lipid Research, 43, 6, 2004. Crossref

  27. Tejuca M, Dı́az I, Figueredo R, Roque L, Pazos F, Martı́nez D, Iznaga-Escobar N, Pérez R, Alvarez C, Lanio M.E, Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line, International Immunopharmacology, 4, 6, 2004. Crossref

  28. Todorovska Aneta, Roovers Rob C., Dolezal Olan, Kortt Alexander A., Hoogenboom Hennie R., Hudson Peter J., Design and application of diabodies, triabodies and tetrabodies for cancer targeting, Journal of Immunological Methods, 248, 1-2, 2001. Crossref

  29. Soper Steven A., Brown Kathlynn, Ellington Andrew, Frazier Bruno, Garcia-Manero Guillermo, Gau Vincent, Gutman Steven I., Hayes Daniel F., Korte Brenda, Landers James L., Larson Dale, Ligler Frances, Majumdar Arun, Mascini Marco, Nolte David, Rosenzweig Zeev, Wang Joseph, Wilson David, Point-of-care biosensor systems for cancer diagnostics/prognostics, Biosensors and Bioelectronics, 21, 10, 2006. Crossref

  30. Revets Hilde, De Baetselier Patrick, Muyldermans Serge, Nanobodies as novel agents for cancer therapy, Expert Opinion on Biological Therapy, 5, 1, 2005. Crossref

  31. Smith Jill P, Verderame Michael F, Ballard Elizabeth N, Zagon Ian S, Functional significance of gastrin gene expression in human cancer cells, Regulatory Peptides, 117, 3, 2004. Crossref

  32. Kratz F, Warnecke A, Riebeseel K, Rodrigues P, Anticancer Drug Conjugates with Macromolecular Carriers, in Polymeric Biomaterials, Revised and Expanded, 2001. Crossref

  33. Lv Xinxin, Zhang Jian, Xu Rui, Dong Yuguo, Sun Aiyou, Shen Yaling, Wei Dongzhi, Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells, Applied Microbiology and Biotechnology, 100, 14, 2016. Crossref

  34. Roth Robert I., Magic Bullets Finally Find Their Mark, Journal of the American Pharmaceutical Association (1996), 41, 3, 2001. Crossref

  35. Augustine Samuel C., Norenberg Jeffrey P., Colcher David M., Vose Julie M., Gobar Lisa S., Dukat Valorie J., Hohenstein Maribeth A., Rutar Frank J., Jacobson David A., Tempero Margaret A., Combination Therapy for Non-Hodgkin’s Lymphoma: An Opportunity for Pharmaceutical Care in a Specialty Practice, Journal of the American Pharmaceutical Association (1996), 42, 1, 2002. Crossref

  36. Cortez-Retamozo Virna, Lauwereys Marc, Hassanzadeh Gh. Gholamreza, Gobert Martine, Conrath Katja, Muyldermans Serge, De Baetselier Patrick, Revets Hilde, Efficient tumor targeting by single-domain antibody fragments of camels, International Journal of Cancer, 98, 3, 2002. Crossref

  37. Beum Paul V., Singh Jaswant, Burdick Michael, Hollingsworth Michael A., Cheng Pi-Wan, Expression of Core 2 β-1,6-N-Acetylglucosaminyltransferase in a Human Pancreatic Cancer Cell Line Results in Altered Expression of MUC1 Tumor-associated Epitopes, Journal of Biological Chemistry, 274, 35, 1999. Crossref

  38. Shunmugaperumal Tamilvanan, Thenrajan Raja Sekharan, Sharma Ruchi, Multifunctional nanosized emulsions for theragnosis of life threatening diseases, in Nanostructures for Drug Delivery, 2017. Crossref

  39. Smallshaw Joan E., Ghetie Victor, Rizo Jose, Fulmer John R., Trahan Linda L., Ghetie Maria-Ana, Vitetta Ellen S., Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice, Nature Biotechnology, 21, 4, 2003. Crossref

  40. Micheel Burkhard, Monoklonale Antikörper, in Grundlagen der Molekularen Medizin, 2003. Crossref

  41. Smallshaw Joan E., Vitetta Ellen S., Ricin Vaccine Development, in Ricin and Shiga Toxins, 357, 2011. Crossref

  42. Behrsing Olaf, Micheel Burkhard, Monoklonale Antikörper: Grundlagen und ihre Bedeutung in Diagnostik und Therapie, in Grundlagen der Molekularen Medizin, 2008. Crossref

  43. Ghetie Victor, Ward E. Sally, Vitetta Ellen S., Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans, in Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2004. Crossref

  44. Murray A., Denton G., Price M. R., Perkins A. C., Antibody targeted therapy: delivery of radionuclides, toxins and drugs, in Cancer Immunology, 2001. Crossref

  45. Borghaei Hossein, Binyamin Liat, Astsaturov Igor, Weiner Louis M., Antibody Therapy of Cancer, in Molecular Targeting in Oncology, 2008. Crossref

  46. Madhusudan Srinivasan, Ganesan Trivadi S., Tyrosine Kinase Inhibitors and Cancer Therapy, in Targeted Interference with Signal Transduction Events, 172, 2007. Crossref

  47. Tassone Pierfrancesco, Goldmacher Victor S., Neri Paola, Gozzini Antonella, Shammas Masood A., Whiteman Kathleen R., Hylander-Gans Linda L., Carrasco Daniel R., Hideshima Teru, Shringarpure Reshma, Shi Jialan, Allam Charles K., Wijdenes John, Venuta Salvatore, Munshi Nikhil C., Anderson Kenneth C., Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells, Blood, 104, 12, 2004. Crossref

  48. Tumor Immunity, in Immunology, Immunopathology, and Immunity, 2001. Crossref

  49. Chen Jia, Yin Sheng, Wu Yongjian, Ouyang Jun, Development of a Native Nanoelectrospray Mass Spectrometry Method for Determination of the Drug-to-Antibody Ratio of Antibody–Drug Conjugates, Analytical Chemistry, 85, 3, 2013. Crossref

  50. West Anthony P., Bjorkman Pamela J., Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor,, Biochemistry, 39, 32, 2000. Crossref

  51. Carter Paul, Improving the efficacy of antibody-based cancer therapies, Nature Reviews Cancer, 1, 2, 2001. Crossref

  52. Tassone Pierfrancesco, Gozzini Antonella, Goldmacher Victor, Shammas Masood A., Whiteman Kathleen R., Carrasco Daniel R., Li Cheng, Allam Charles K., Venuta Salvatore, Anderson Kenneth C., Munshi Nikhil C., In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901- N 2′-Deacetyl- N 2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells, Cancer Research, 64, 13, 2004. Crossref

  53. Valadon Philippe, Garnett Jeff D., Testa Jacqueline E., Bauerle Marc, Oh Phil, Schnitzer Jan E., Screening phage display libraries for organ-specific vascular immunotargeting in vivo , Proceedings of the National Academy of Sciences, 103, 2, 2006. Crossref

  54. Brekke Ole Henrik, Sandlie Inger, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nature Reviews Drug Discovery, 2, 1, 2003. Crossref

Próximos artigos

PRMT6 promotes the immune evasion of gastric cancer via upregulating ANXA1 Liang Xu, Fenger Zhang, Binqi Yu, Shengnan Jia, Sunfu Fan PURPL promotes M2 macrophage polarization in lung cancer via regulating RBM4/xCT signaling Jipeng Guo, Chongwen Gong, Hao Wang SIAH1 promotes the pyroptosis of cardiomyocytes in diabetic cardiomyopathy via regulating IκB-α/NF-κB signaling Jinbin Wu, Yaoming Yan SLC7A2-mediated lysine catabolism inhibits immunosuppression in triple negative breast cancer Yuanyuan Sun, Yaqing Li, Chengying Jiang, Chenying Liu, Yuanming Song SIAH2-mediated degradation of ACSL4 inhibits the anti-tumor activity of CD8+ T cells in hepatocellular carcinoma Fangzheng Shu, Yuhua Shi, Xiangxiang Shan, Wenzhang Zha, Rengen Fan, Wanjiang Xue RBM15-mediated N6-methyl adenosine (m6A) modification of EZH2 drives the epithelial-mesenchymal transition of cervical cancer Ruixue Wang, Wenhua Tan Evidence-Based Storytelling and A Strategic Roadmap to Promote Cancer Prevention Via Adolescent HPV Vaccination in Northern New England Matthew Dugan, Gary Stein, Jan Carney, Sheila Clifford-Bova KDM4A-AS1 promotes cell proliferation, migration and invasion via the miR-4306/STX6 axis in hepatocellular carcinoma Wei Cao, Yuhan Ren, Ying Liu, Guoshu Cao, Zhen Chen, Fan Wang HDAC1-mediated downregulation of NEU1 exacerbates the aggressiveness of cervical cancer Nanzi Xie, Sisi Mei, Changlan Dai, Wei Chen Effect of miR-26b-5p on progression of acute myeloid leukemia by regulating USP48-mediated Wnt/β-catenin pathway Yu Xie, Lin Tan, Kun Wu, Deyun Li, Chengping Li
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain